Proposal for a prospective registry for moyamoya disease in Japan

Ken Kazumata, Masaki Ito, Haruto Uchino, Hiroshi Nishihara, Kiyohiro Houkin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The number of clinical research papers published worldwide on moyamoya disease (MMD) has increased recently. However, the majority of the literature comprises retrospective single-center studies collecting data on small numbers of patients. Several multi-center studies are ongoing in Japan; however, the current data are insufficient for comprehensively outlining the various characteristics of MMD. To enhance our knowledge on epidemiologic, vascular, and genetic aspects of MMD, a prospective multicenter registry will be established in Japan that will help to streamline clinical research as well as improve clinical treatments and long-term outcomes. Patients with MMD or secondary moyamoya syndrome referred to the participating centers will be invited to the registry. Demographic and physiological parameters, along with neuroimaging data will be collected chronologically. Clinical events, including neurological, medical, and surgical interventions will be recorded. Whole blood samples will be collected. Extra- and intracranial vascular tissue, and/or cerebrospinal fluid will also be collected from patients who undergo surgical revascularization. These biospecimens will be stored at the repositories and utilized for genome-wide association studies for identifying genetic variants, as well as tissue-specific proteomic, and/or molecular analyses. Ethics approval will be obtained at all facilities collecting biospecimens. The registry will provide descriptive statistics on functional outcomes, surgical techniques used, medications, and neurological events stratified according to patients’ clinical characteristics. We expect this study to provide novel insights in the management of MMD patients and design better therapies.

Original languageEnglish
Pages (from-to)66-72
Number of pages7
JournalNeurologia Medico-Chirurgica
Volume57
Issue number2
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Moyamoya Disease
Registries
Japan
Blood Vessels
Genome-Wide Association Study
Research
Neuroimaging
Ethics
Proteomics
Cerebrospinal Fluid
Demography
Therapeutics

Keywords

  • Clinical research
  • Epigenetics
  • Intractable diseases
  • Moyamoya disease
  • Registry

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Proposal for a prospective registry for moyamoya disease in Japan. / Kazumata, Ken; Ito, Masaki; Uchino, Haruto; Nishihara, Hiroshi; Houkin, Kiyohiro.

In: Neurologia Medico-Chirurgica, Vol. 57, No. 2, 01.01.2017, p. 66-72.

Research output: Contribution to journalArticle

Kazumata, Ken ; Ito, Masaki ; Uchino, Haruto ; Nishihara, Hiroshi ; Houkin, Kiyohiro. / Proposal for a prospective registry for moyamoya disease in Japan. In: Neurologia Medico-Chirurgica. 2017 ; Vol. 57, No. 2. pp. 66-72.
@article{b4e53862b7e24a56a0b3e0c20d11eaeb,
title = "Proposal for a prospective registry for moyamoya disease in Japan",
abstract = "The number of clinical research papers published worldwide on moyamoya disease (MMD) has increased recently. However, the majority of the literature comprises retrospective single-center studies collecting data on small numbers of patients. Several multi-center studies are ongoing in Japan; however, the current data are insufficient for comprehensively outlining the various characteristics of MMD. To enhance our knowledge on epidemiologic, vascular, and genetic aspects of MMD, a prospective multicenter registry will be established in Japan that will help to streamline clinical research as well as improve clinical treatments and long-term outcomes. Patients with MMD or secondary moyamoya syndrome referred to the participating centers will be invited to the registry. Demographic and physiological parameters, along with neuroimaging data will be collected chronologically. Clinical events, including neurological, medical, and surgical interventions will be recorded. Whole blood samples will be collected. Extra- and intracranial vascular tissue, and/or cerebrospinal fluid will also be collected from patients who undergo surgical revascularization. These biospecimens will be stored at the repositories and utilized for genome-wide association studies for identifying genetic variants, as well as tissue-specific proteomic, and/or molecular analyses. Ethics approval will be obtained at all facilities collecting biospecimens. The registry will provide descriptive statistics on functional outcomes, surgical techniques used, medications, and neurological events stratified according to patients’ clinical characteristics. We expect this study to provide novel insights in the management of MMD patients and design better therapies.",
keywords = "Clinical research, Epigenetics, Intractable diseases, Moyamoya disease, Registry",
author = "Ken Kazumata and Masaki Ito and Haruto Uchino and Hiroshi Nishihara and Kiyohiro Houkin",
year = "2017",
month = "1",
day = "1",
doi = "10.2176/nmc.st.2016-0153",
language = "English",
volume = "57",
pages = "66--72",
journal = "Neurologia Medico-Chirurgica",
issn = "0470-8105",
publisher = "Japan Neurosurgical Society",
number = "2",

}

TY - JOUR

T1 - Proposal for a prospective registry for moyamoya disease in Japan

AU - Kazumata, Ken

AU - Ito, Masaki

AU - Uchino, Haruto

AU - Nishihara, Hiroshi

AU - Houkin, Kiyohiro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The number of clinical research papers published worldwide on moyamoya disease (MMD) has increased recently. However, the majority of the literature comprises retrospective single-center studies collecting data on small numbers of patients. Several multi-center studies are ongoing in Japan; however, the current data are insufficient for comprehensively outlining the various characteristics of MMD. To enhance our knowledge on epidemiologic, vascular, and genetic aspects of MMD, a prospective multicenter registry will be established in Japan that will help to streamline clinical research as well as improve clinical treatments and long-term outcomes. Patients with MMD or secondary moyamoya syndrome referred to the participating centers will be invited to the registry. Demographic and physiological parameters, along with neuroimaging data will be collected chronologically. Clinical events, including neurological, medical, and surgical interventions will be recorded. Whole blood samples will be collected. Extra- and intracranial vascular tissue, and/or cerebrospinal fluid will also be collected from patients who undergo surgical revascularization. These biospecimens will be stored at the repositories and utilized for genome-wide association studies for identifying genetic variants, as well as tissue-specific proteomic, and/or molecular analyses. Ethics approval will be obtained at all facilities collecting biospecimens. The registry will provide descriptive statistics on functional outcomes, surgical techniques used, medications, and neurological events stratified according to patients’ clinical characteristics. We expect this study to provide novel insights in the management of MMD patients and design better therapies.

AB - The number of clinical research papers published worldwide on moyamoya disease (MMD) has increased recently. However, the majority of the literature comprises retrospective single-center studies collecting data on small numbers of patients. Several multi-center studies are ongoing in Japan; however, the current data are insufficient for comprehensively outlining the various characteristics of MMD. To enhance our knowledge on epidemiologic, vascular, and genetic aspects of MMD, a prospective multicenter registry will be established in Japan that will help to streamline clinical research as well as improve clinical treatments and long-term outcomes. Patients with MMD or secondary moyamoya syndrome referred to the participating centers will be invited to the registry. Demographic and physiological parameters, along with neuroimaging data will be collected chronologically. Clinical events, including neurological, medical, and surgical interventions will be recorded. Whole blood samples will be collected. Extra- and intracranial vascular tissue, and/or cerebrospinal fluid will also be collected from patients who undergo surgical revascularization. These biospecimens will be stored at the repositories and utilized for genome-wide association studies for identifying genetic variants, as well as tissue-specific proteomic, and/or molecular analyses. Ethics approval will be obtained at all facilities collecting biospecimens. The registry will provide descriptive statistics on functional outcomes, surgical techniques used, medications, and neurological events stratified according to patients’ clinical characteristics. We expect this study to provide novel insights in the management of MMD patients and design better therapies.

KW - Clinical research

KW - Epigenetics

KW - Intractable diseases

KW - Moyamoya disease

KW - Registry

UR - http://www.scopus.com/inward/record.url?scp=85012267016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012267016&partnerID=8YFLogxK

U2 - 10.2176/nmc.st.2016-0153

DO - 10.2176/nmc.st.2016-0153

M3 - Article

VL - 57

SP - 66

EP - 72

JO - Neurologia Medico-Chirurgica

JF - Neurologia Medico-Chirurgica

SN - 0470-8105

IS - 2

ER -